Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vidit Sharma

Showing results (111-120 of 187) with videos related to

Pageof 19
Sort By:
The Journal of Urology|September 6, 2022
Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov ModelVidit Sharma, Kevin M Wymer, Daniel D Joyce, et al.
Scandinavian Journal of Urology|January 3, 2019
Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancerMarco Moschini, Vidit Sharma, Matteo Soligo, et al.
Urology|June 1, 2025
Characterizing the Hospital Caseload-Outcome Relationship for Radical Nephrectomy With Inferior Vena Cava Tumor Thrombectomy: Analysis From the National Inpatient SampleGrant M Henning, Ekamjit S Deol, Ranveer Vasdev, et al.
European Urology Oncology|December 12, 2022
International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell CarcinomaTimothy D Lyon, Eduard Roussel, Vidit Sharma, et al.
The Journal of Urology|June 24, 2022
Unplanned Conversion From Partial to Radical Nephrectomy: An Analysis of Incidence, Etiology, and Risk FactorsMatvey Tsivian, Daniel D Joyce, Vignesh T Packiam, et al.
Urology|April 16, 2026
Long-Term Outcomes of Partial Cystectomy for Urothelial Carcinoma In the Era of Bladder PreservationAustin Martin, Chloe Shi, Gianni Morales Martinez, et al.
The Journal of Urology|May 18, 2026
<b>Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST</b>, <b>POTOMAC, and ALBAN</b>Daniel D Joyce, Vidit Sharma, Grace E Ratcliff, et al.
Cancer|October 17, 2022
Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER dataDaniel D Joyce, Kevin M Wymer, Vidit Sharma, et al.
Kidney Medicine|January 14, 2025
Glomerular and Nephron Size and Kidney Disease Outcomes: A Comparison of Manual Versus Deep Learning Methods in Kidney PathologyJaidip M Jagtap, Andrew R Janowczyk, Yijiang Chen, et al.
The Journal of Urology|March 20, 2020
Cost-Effectiveness of Maintenance bacillus Calmette-Guérin for Intermediate and High Risk Nonmuscle Invasive Bladder CancerVidit Sharma, Kevin M Wymer, Bijan J Borah, et al.
Pageof 19

Showing results (111-120 of 187) with videos related to

Sort By:
Pageof 19
The Journal of Urology|September 6, 2022
Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov ModelVidit Sharma, Kevin M Wymer, Daniel D Joyce, et al.
Scandinavian Journal of Urology|January 3, 2019
Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancerMarco Moschini, Vidit Sharma, Matteo Soligo, et al.
Urology|June 1, 2025
Characterizing the Hospital Caseload-Outcome Relationship for Radical Nephrectomy With Inferior Vena Cava Tumor Thrombectomy: Analysis From the National Inpatient SampleGrant M Henning, Ekamjit S Deol, Ranveer Vasdev, et al.
European Urology Oncology|December 12, 2022
International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell CarcinomaTimothy D Lyon, Eduard Roussel, Vidit Sharma, et al.
The Journal of Urology|June 24, 2022
Unplanned Conversion From Partial to Radical Nephrectomy: An Analysis of Incidence, Etiology, and Risk FactorsMatvey Tsivian, Daniel D Joyce, Vignesh T Packiam, et al.
Urology|April 16, 2026
Long-Term Outcomes of Partial Cystectomy for Urothelial Carcinoma In the Era of Bladder PreservationAustin Martin, Chloe Shi, Gianni Morales Martinez, et al.
The Journal of Urology|May 18, 2026
<b>Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST</b>, <b>POTOMAC, and ALBAN</b>Daniel D Joyce, Vidit Sharma, Grace E Ratcliff, et al.
Cancer|October 17, 2022
Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER dataDaniel D Joyce, Kevin M Wymer, Vidit Sharma, et al.
Kidney Medicine|January 14, 2025
Glomerular and Nephron Size and Kidney Disease Outcomes: A Comparison of Manual Versus Deep Learning Methods in Kidney PathologyJaidip M Jagtap, Andrew R Janowczyk, Yijiang Chen, et al.
The Journal of Urology|March 20, 2020
Cost-Effectiveness of Maintenance bacillus Calmette-Guérin for Intermediate and High Risk Nonmuscle Invasive Bladder CancerVidit Sharma, Kevin M Wymer, Bijan J Borah, et al.
Pageof 19